Parkinson’s disease biomarker research continues to advance with the objectives of enabling earlier detection of neurodegeneration, elucidating disease mechanisms, identifying potential therapeutic targets as well as monitoring disease progression. While many promising biomarkers have been proposed, the ideal biomarker — with adequate sensitivity or specificity — remains elusive.
From α-synuclein to advanced magnetic resonance imaging (MRI) techniques, this webinar will cover both traditional Parkinson’s disease biomarkers and the potential utility of emerging biomarkers, such as microRNA (miRNA), microbiome and multimodal approaches.
Citing longitudinal research studies and recent clinical trials, the featured speakers will share the potential utility of fluid-based biomarkers and imaging biomarkers, discussing how each may help track drug efficacy and advance clinical trials.
Join this webinar to learn how fluid and imaging biomarkers can impact study design and patient selection in Parkinson’s disease clinical trials.
Robert Martone, Associate Director, Neurology Biomarkers, Biomarkers Solution Center, Labcorp Drug Development
Robert Martone is a research scientist with deep expertise in neurodegeneration, neuro-oncology, biomarkers and drug discovery. He investigated hereditary neuropathies and the molecular biology of the blood-brain barrier at Columbia University, and subsequently managed a portfolio of drug discovery programs at Wyeth Neuroscience targeting Alzheimer’s and Parkinson’s disease. He was the Neuroscience Therapeutic Area Lead for the Covance Biomarker Center of Excellence, and later established a protein biomarker laboratory at St. Jude Children’s Research Hospital. More recently, he was Director of Preclinical Research at Cognition Therapeutics, and later supported late stage biomarker and diagnostics efforts at Biogen. He is currently Associate Director supporting Neurology Biomarkers at the Labcorp Biomarker Solutions Center.
Hiba Kazmi, PhD, Biomarker Scientist, IXICO
Hiba Kazmi graduated from King’s College London with a master’s degree in clinical neuroscience and holds a PhD from University College London (UCL) Queen Square Institute of Neurology. Her PhD investigated the presence of clinical and imaging features associated with prodromal Parkinson’s disease in patients with late onset depression. She also has experience in clinical settings, including working with patients with psychiatric disorders such as depression and schizophrenia.
Hiba is currently a Biomarker Scientist at IXICO where she is the imaging lead for Parkinson’s disease and also works in other disease areas including progressive supranuclear palsy and Alzheimer’s disease.
Antoniya Todorova, MD, PhD, Medical Director, Labcorp
Antoniya Todorova is a board-certified neurologist with over 15 years of clinical and research experience in neurodegenerative disorders and demyelinating diseases. She obtained her PhD degree with a thesis on the quality of life in patients with Parkinson’s disease and was involved in academic and clinical research. Dr. Todorova worked as a Clinical Research Fellow at King’s College Hospital, London and during this period she was involved in academic research focused on non-motor symptoms and continuous drug treatment in Parkinson’s disease. She has been an Investigator in more than 20 clinical drug trials in Parkinson’s disease, Alzheimer disease and multiple sclerosis.
Her pharmaceutical industry expertise is focused on the neurosciences across Phase I to Phase IV of clinical development, mainly in Parkinson’s disease and multiple sclerosis. Currently she is a Medical Director in the Neuroscience team at LabCorp Drug Development.
Who Should Attend?
Researchers, scientists, clinicians, academicians and professionals from pharmaceutical companies, bio-pharma companies as well as universities and research institutes working in:
- Biomarker discovery/development
- Biomarkers for Neurological disorders
- Clinical Biomarkers
- Companion Diagnostics
- Personalized Medicine
- Tailored Therapeutics
- Translational Medicine and Science
What You Will Learn
In this webinar, attendees will:
- Learn current biomarker strategies in Parkinson’s disease clinical trials
- Hear about emerging approaches for Parkinson’s disease biomarkers, such as advanced magnetic resonance imaging (MRI)
- Understand how fluid and imaging biomarkers can impact study design and patient selection in Parkinson’s disease clinical trials
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. Learn more about Labcorp at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.